Pharmacological inhibition of PP2A by LB-100 partially restored nab-PTX sensitivity and inhibited nab-PTX resistant xenograft growth alone or in combination with nab-PTX, supporting PP2A as a novel therapeutic target against nab-PTX resistant ESCC. Here, PTPA is linked to esophageal squamous cell carcinoma.